Ultime notizie per SIGA Technologies (NASDAQ:SIGA) Azioni

SIGA Technologies

SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.

SIGA Technologies Inc

Biotech

News

General

SIGA

SIGA Enters Exclusive License Agreement With Vanderbilt University To Obtain A License To A Portfolio Of Preclinical Fully Human Poxvirus Monoclonal Antibodies

The contract was executed in response to a request from the Ministry of Health in Morocco to make the therapy available in the country and help prepare and protect its citizens against any potential mpox outbreak.
Tecovirimat is approved in the U.S., Canada, and the EU, and while it has also been available in Africa through clinical trials and as part of the World Health Organization&#39;s emergency use access protocol, this agreement marks SIGA&#39;s first commercial sale of TPOXX on the continent.

Contracts

SIGA Technologies Enters Agreement To Supply TPOXX (Tecovirimat) In Morocco

The World Health Organization announced a new strategic preparedness and response plan Monday in the fight against mpox, two weeks after declaring a public health emergency<a href="https://www.benzinga.com/general/health-care/24/08/40381585/who-declares-mpox-public-health-emergency-coordinated-international-response-essential-to-hal"> on the outbreak.</a>
What Happened: The WHO announced a new plan in its fight against the outbreak of mpox. The plan comes as several companies are<a href="https://www.benzinga.com/news/24/08/40439999/geovax-labs-stock-continues-to-surge-whats-going-on"> ramping up efforts</a> to launch or increase output of mpox vaccines and treatment options.
The <a href="https://www.who.int/news/item/26-08-2024-global-strategic-preparedness-and-response-plan-launched-by-who-to-contain-mpox-outbreak">plan </a>calls for $135 million in funding for the WHO response and for member states and partners. Among the partners are communities, researchers and the Africa Centres for Disease Control and Prevention.
Funding will help with surveillance, prevention, readiness and the response to fight outbreaks of mpox, the WHO said.
The WHO said it will take part in strategic vaccination efforts to focus on high-risk individuals, which includes health care workers and those with close contact to recent cases.
"The mpox outbreaks in the Democratic Republic of the Congo and neighboring countries can be controlled, and can be stopped," WHO Director-General Dr. Tedros Adhanom Ghebreyesus said. 
"Doing so requires a comprehensive and coordinated plan of action between international agencies and national and local partners, civil society, researchers and manufacturers, and our Member States."
A virtual scientific conference will be held on Aug. 29 and Aug 30 to share mpox research and outbreak control goals from the WHO, Africa CDC and the National Institute of Allergy and Infectious Diseases.
Read Also: <a href="https://www.benzinga.com/news/large-cap/24/08/40559658/diagnostic-giants-labcorp-roche-to-ramp-up-testing-capacity-amid-global-concerns-over-new-mpox-str">Diagnostic Giants Labcorp, Roche To Ramp Up Testing Capacity Amid Global Concerns Over New Mpox Strain</a>
Why It's Important: The six-month plan is viewed as the critical step in stopping mpox outbreaks from spreading further or faster.
On Monday, Germany announced it will donate 100,000 mpox vaccine doses from its stockpile to help with the outbreak prevention, as reported by Reuters. Germany will keep a minimum stock of mpox vaccines, the report said. 
There have been 3,326 confirmed cases of mpox in Africa in 2024, with 590 deaths across 12 countries, according to the Africa Centres for Disease Control and Prevention, as <a href="https://thehill.com/policy/healthcare/4847877-who-releases-mpox-outbreak-plan/">reported </a>by The Hill. A total of 17,979 suspected mpox cases have been reported. 
Shares of companies that have mpox vaccines or treatments have been highly volatile over the last two weeks. The list includes Bavarian Nordic (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BVNRY#OTC">BVNRY</a>) and Emergent Biosolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>), both of which have WHO-recommended vaccines
GeoVax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) and SIGA Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) have also been highly volatile. GeoVax has a mpox vaccine in clinical development. SIGA Technologies has Tpoxx, which is a treatment for mpox.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40554882/tonix-pharma-collaborates-with-worlds-largest-vaccine-manufacturer-for-mpox-vaccine">Tonix Pharma Collaborates With World&#8217;s Largest Vaccine Manufacturer For Mpox Vaccine</a></li>
</ul>
Illustration via Shutterstock.

Health Care

Global

Movers

Trading Ideas

BVNRY

GOVX

WHO Seeks $135M In Funding To Fight Mpox: Outbreak 'Can Be Controlled, And Can Be Stopped'

On Wednesday, SIGA Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>)&nbsp;announced a new contract with the&nbsp;U.S. Department of Defense&nbsp;(DOD) to procure approximately <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/g40493842/siga-announces-new-contract-awarded-by-u-s-department-of-defense-for-the-procurement-of-9-million-" rel="noreferrer noopener">$9 million&nbsp;of TPOXX</a>.
This award is comprised primarily of oral TPOXX, with a small amount of intravenous (IV) TPOXX, and represents the third procurement contract award from the DOD over the past three years.
The company also received approximately&nbsp;$27 million&nbsp;to develop the post-exposure Prophylaxis indication for oral TPOXX.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/asia/24/08/40446949/mpox-variant-sparks-global-concern-as-europe-china-ramp-up-screening" rel="noreferrer noopener">Mpox Variant Sparks Global Concern As Europe, China Ramp Up Screening</a>.
Inclusive of this award, SIGA currently has approximately $154 million of outstanding oral and IV TPOXX&nbsp;orders, more than 85% of which were generated within the past three months.
Edison report adds that SIGA continues to advance its growth strategy, with recent contract wins from BARDA and the Department of Defense significantly boosting its order book.
The company is set to deliver IV TPOXX under orders from July 2023 ($25 million), and August 2022 ($8.4 million, of which $17.8 million from a $26 million order was already delivered in the first half of 2024).
These are part of approximately $155 million in outstanding TPOXX (oral and IV) orders.
SIGA anticipates delivering the remaining August 2022 IV TPOXX order and 80% of the BARDA oral TPOXX order in the second half of 2024.
While delivery timeline details are yet to be disclosed, Edison Group&#8217;s report notes that new DoD order to start at least being partially serviced in fiscal year 2025.
Recently, the National Institutes of Health&#8217;s National Institute of Allergy and Infectious Diseases (NIAID) announced topline results from a preliminary analysis of the PALM 007 trial of<a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40394363/in-nih-cosponsored-monkeypox-virus-study-in-congo-siga-technologies-antiviral-tecovirimat-did-not" rel="noreferrer noopener"> tecovirimat for mpox</a>.
NIAID reported that the study did not meet its primary endpoint of a statistically significant improvement in time to lesion resolution within 28 days post-randomization for patients in the Democratic Republic of the Congo with mpox who were administered SIGA&#8217;s tecovirimat versus placebo, weighing on the share price.
Edison analysts expect an improvement in investor sentiment with the recent DoD contract win.
&#8220;We maintain that mpox continues to be an opportunity for SIGA on the heels of the WHO&nbsp;declaration of a global health emergency,&#8221; the analysts added.
Price Action: SIGA stock is up 4.07% at $9.72 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40528702/europe-approves-modernas-rsv-vaccine-for-adults-60-and-over" target="_blank" rel="noreferrer noopener">Europe Approves Moderna&#8217;s RSV Vaccine For Adults 60 And Over</a>.</li>
</ul>

Government

Government Contract Win May Improve Investor Sentiment For SIGA Tech After Disappointing Trial Data: Analyst

WIIM

SIGA Technologies shares are trading higher after the company announced it was awarded a new contract by the U.S. Department of Defense for the procurement of $9 million worth of TPOXX.

SIGA Technologies, Inc. (SIGA) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>), a commercial-stage pharmaceutical company and leader in infectious diseases, today announced a new contract with the&nbsp;U.S. Department of Defense&nbsp;(DOD) for the procurement of approximately $9 million&nbsp;of TPOXX&#xAE; (Contract number: W911SR24C0030). This award is comprised primarily of oral TPOXX&#xAE;, with a small amount of intravenous (IV) TPOXX&#xAE;, and represents the third procurement contract award from the DOD over the past three years. &nbsp;
SIGA has been collaborating with the DOD's&nbsp;Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to develop the Post-exposure Prophylaxis (PEP) indication for oral TPOXX&#xAE;, and this work has been supported by a development contract with a value of approximately&nbsp;$27 million&nbsp;(Contract number: MCDC1901-001-2019-400) as well as a Cooperative Research and Development Agreement.

SIGA Awarded Contract By U.S. Department Of Defense For The Procurement Of $9M Of TPOXX

Authorities in Europe and China are expediting screening for a <a href="https://www.benzinga.com/general/health-care/24/08/40381585/who-declares-mpox-public-health-emergency-coordinated-international-response-essential-to-hal">deadly new version </a>of mpox that has spread across regions of Africa and has been found in Europe.
The European Center for Disease Prevention and Control on Friday raised its risk assessment for mpox and forecasted more imported cases after a new strain called clade I was confirmed in Sweden, <a href="https://www.axios.com/2024/08/19/mpox-mobilization-intensifies-outside-of-africa">Axios</a> reported.
Pakistan&#8217;s health ministry reported Friday that it identified an mpox case and was conducting sequencing to determine if it is the new strain.
China&#8217;s customs administration said it would look for signs of mpox in people and goods entering the country over the next six months, the state-run, English-speaking news TV channel CTGN reported.
According to the <a href="https://www.cdc.gov/cfa-modeling-and-forecasting/mpox-transmission-technical-brief/index.html">CDC</a>, the Democratic Republic of the Congo&#8217;s ongoing mpox outbreak, driven by the more transmissible and severe Clade I virus, involves multiple transmission modes, including household and sexual exposures, with 70% of cases in children under 15.
Read Also: <a href="https://www.benzinga.com/news/24/08/40444353/virax-biolabs-shares-climb-with-mpox-cases-what-to-know">Virax Biolabs Shares Climb With Mpox Cases: What To Know</a>
More than 16,000 new cases and 511 deaths have been reported in Africa this year, and nine countries have reported confirmed new cases of mpox in recent weeks.
The World Health Organization last week declared mpox a global health emergency, acknowledging that it would likely spread across Africa and outside the continent. The organization is working with countries and drugmakers on vaccine donations.
Clade I is different from the less severe Clade II strain of mpox that caused the global outbreak in 2022, but they both share similar flu-like symptoms and produce a rash that at first resembles pimples or blisters.
In the U.S.,&nbsp;the Centers for Disease Control and Prevention has told doctors to watch out for the new mpox strain, but it also said that the risk to the public is very low.
Two vaccines &#8212; Jynneos, made by Bavarian Nordic (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BVNRY#OTC">BVNRY</a>) and LC16, from KM Biologics &#8212; have received emergency authorizations. Bavarian Nordic has asked the European Union&#8217;s drug regulator to expand Jynneos&#8217; use to 12- to 17-year-olds, an age group especially at risk from clade 1.
A National Institutes of Health study showed the smallpox antiviral drug tecovirimat, which is made by SIGA Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) did not lower the duration of mpox lesions among children and adults with Clade I mpox in the DRC.
Price Action: Shares of Bavarian Nordic were down 1.79% to $13.70 as SIGA declined 0.29% to $10.46 at the time of publication Monday, while most of the exchange-traded funds that cover the segment gained.
<ul>
<li>Amplify Treatments, Testing and Advancements ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GERM#NYSE">GERM</a>) fell 0.35%.</li>
<li>Roundhill Acquirers Deep Value ETF ARCA: DEEP) gained 0.62%.</li>
<li>Invesco NASDAQ Future Gen 200 ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQS#NASDAQ">QQQS</a>) picked up 0.80%.</li>
<li>VictoryShares Small Cap Free Cash Flow ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFLO#NASDAQ">SFLO</a>) went up 0.93%.</li>
<li>First Trust Dow Jones Select MicroCap Index Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDM#NYSE">FDM</a>) rose 0.46%.</li>
</ul>
Read Now:
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40439999/geovax-labs-stock-continues-to-surge-whats-going-on">GeoVax Labs Stock Continues To Surge: What&#8217;s Going On?</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Asia

ETFs

DEEP

First Trust/First Trust Dow Jones Select MicroCap Index Fund

ETFMG Treatments Testing and Advancements ETF

GERM

QQQS

SFLO

Mpox Variant Sparks Global Concern As Europe, China Ramp Up Screening

So-called &#8220;bull traps&#8221; often frustrate traders, as they did on Wednesday, snaring shares of SIGA Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) — and there may be <a href="https://www.benzinga.com/money/bull-trap-vs-bear-trap">another one today</a>.
That's why it&#8217;s our ‘<a href="https://www.benzinga.com/topic/stock-of-the-day">Stock of the Day</a>'.
SIGA shares have been very active because of a surge in Mpox (The World Health Organization ceased using the term Monkey Pox in November 2022 to reduce the stigma and association with monkeys). 
SIGA produces treatments for this disease. The New York-based company released disappointing trial data for a drug to treat Mpox on Thursday, Aug. 15, causing the stock to fall almost 20%. However, it jumped more than 15% early Friday.
Read Also: <a href="https://www.benzinga.com/news/24/08/40402519/emergent-biosolutions-bavarian-nordic-geovax-and-siga-technologies-shares-are-making-big-moves-thurs">Emergent Biosolutions, Bavarian Nordic, GeoVax And SIGA Technologies Shares Are Making Big Moves Thursday</a>
What Is A Bull Trap? A bull trap is akin to a false breakout.  It looks like a stock is going to break out and keep moving higher. But the sellers quickly overpowered the buyers and pushed the stock back below the resistance.
Resistance is a large group of traders and investors who are trying to sell shares close to the same price. As you can see on the chart, there has been resistance for SIGA around $10.50.
Sometimes when a stock reaches resistance it reverses and heads lower. This happened with SIGA in late July and early May.
This occurs when some of the people who created the resistance with their sell orders become concerned that other sellers will undercut them. They know that the buyers will go to whoever is willing to sell at the lowest price.
So, they reduce the prices they are willing to sell at. Other concerned sellers see this and do the same. It results in a snowball effect that pushes the price lower.
But sometimes the stock ‘breaks out' and moves above the resistance.
Breakouts can signal a bullish dynamic. It could mean that the traders and investors who created the resistance with their sell orders have either finished or canceled.
This means a large amount of the supply of shares is gone. If buyers enter the market, they will have a difficult time finding people to sell shares to them.
As a result, they will need to increase the prices they are willing to pay or the sellers won't be interested. This price action could force the shares into a new uptrend.
Sometimes the shares trade above the resistance and it looks like it's a breakout. But it's a ‘head fake'. The sellers have just been on the sidelines.
They come back into the market, overpower the buyers, and push the price lower. This is the ‘false breakout' or ‘bull trap'.
But savvy traders can often profit from these dynamics by going from long to short. &nbsp;Bull traps can be a good contrarian signal.
They tend to be followed by meaningful moves lower. SIGA may be about to enter a downtrend.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/08/40419054/gold-prices-hit-all-time-highs-of-2-500-as-traders-jump-on-rate-cut-train-mining-stocks-on-the-mov">Gold Prices Hit All-Time Highs Of $2,500 As Traders Jump On Rate-Cut Train: Mining Stocks On The Move Friday</a></li>
</ul>
Image: Flickr

Short Ideas

Technicals

Stock Of The Day: Bull Trap Snares SIGA Technologies On Heels Of Mpox Study

U.S. stocks were mixed, with the Dow Jones index falling around 0.1% on Friday.
Shares of H&amp;R Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRB#NYSE">HRB</a>) rose sharply during Friday's session after the company reported better-than-expected fourth-quarter financial results and issued <a href="https://www.benzinga.com/news/earnings/24/08/40407075/h-r-block-q4-earnings-revenue-beat-eps-beat-strong-guidance-1-5b-buyback-stock-up-9">FY25 guidance above estimates.</a>
H&amp;R Block reported quarterly earnings of $1.89 per share which beat the analyst consensus estimate of $1.74. The company reported quarterly sales of $1.063 billion which beat the analyst consensus estimate of $1.028 billion.
Also, the company announced a quarterly dividend increase and $1.5 billion share repurchase authorization.
H&amp;R Block shares jumped 16.4% to $66.73 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares jumped 25% to $10.82. Shares of vaccine and mpox-related stocks traded higher after the WHO declared it a global health emergency.</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) surged 16.4% to $36.52. AST SpaceMobile recently said its first five commercial satellites are on target for orbital launch in the first half of September.</li>
<li>Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) gained 16% to $6.76. Today, the company said it has successfully packed and shipped two Mars-bound spacecraft to Cape Canaveral, FL, in readiness for launch.</li>
<li>Planet Labs PBC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) gained 16% to $2.520 after the company announced that its first hyperspectral satellite, Tanager-1, along with 36 SuperDoves (Flock 4BE), will launch on the Transporter-11 rideshare mission with SpaceX on August 16.</li>
<li>Jumia Technologies AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JMIA#NASDAQ">JMIA</a>) rose 14.8% to $5.63. Jumia announced completion of at-the-market offering.</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) gained 14.6% to $0.8482. Cantor Fitzgerald analyst Andres Sheppard reiterated Polestar Automotive with an Overweight and maintained a $3 price target.</li>
<li>SIGA Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) gained 14.6% to $11.01.</li>
<li>Ambipar Emergency Response (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMBI#NYSE">AMBI</a>) climbed 10.5% to $5.99.</li>
<li>Treace Medical Concepts, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>) rose 9.2% to $6.53.</li>
<li>CI&amp;T Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CINT#NYSE">CINT</a>) shares gained 7.4% to $7.25 after the company reported better-than-expected second-quarter financial results.</li>
<li>QXO, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NYSE">QXO</a>) gained 7.1% to $12.15.</li>
<li>Cellebrite DI Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLBT#NYSE">CLBT</a>) rose 6.7% to $15.96. Cellebrite, on Thursday, reported better-than-expected second-quarter financial results and raised its FY24 revenue guidance above estimates.</li>
<li>JD.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) gained 5.5% to $28.51.</li>
<li>Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) rose 4.9% to $83.44 after multiple analysts raised their price targets on the stock following Thursday&#8217;s earnings report.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40417110/jim-cramer-this-financial-stock-is-a-buy-core-scientific-is-a-very-overvalued-situation"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40417110/jim-cramer-this-financial-stock-is-a-buy-core-scientific-is-a-very-overvalued-situation">Jim Cramer: This Financial Stock Is A Buy, Core Scientific Is A &#8216;Very Overvalued Situation&#8217;</a></li>
</ul>

Intraday Update

Markets

AMBI

ASTS

BABA

CINT

CLBT

JMIA

PSNY

RKLB

TMCI

H&R Block Posts Upbeat Earnings, Joins Alibaba Group, CI&T And Other Big Stocks Moving Higher On Friday

<a href="https://www.ecdc.europa.eu/en/news-events/ecdc-recommends-enhancing-preparedness-more-imported-cases-clade-i-mpox-highly-likely" title="https://www.ecdc.europa.eu/en/news-events/ecdc-recommends-enhancing-preparedness-more-imported-cases-clade-i-mpox-highly-likely">https://www.ecdc.europa.eu/en/news-events/ecdc-recommends-enhancing-preparedness-more-imported-cases-clade-i-mpox-highly-likely</a>

ECDC Warns of Likely Mpox Cases in EU/EEA from Africa, But Low Risk of Sustained Transmission with Quick Diagnosis and Control

U.S. stocks traded higher toward the end of trading, with the S&amp;P 500 gaining around 1.5% on Thursday.
The Dow traded up 1.23% to 40,501.91 while the NASDAQ jumped 2.28% to 17,584.56. The S&amp;P 500 also rose, gaining, 1.52% to 5,538.34.
Check This Out: <a href="https://www.benzinga.com/news/24/08/40391883/wall-streets-most-accurate-analysts-spotlight-on-3-materials-stocks-with-over-4-dividend-yields"> Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Materials Stocks With Over 4% Dividend Yields</a>
Leading and Lagging Sectors Consumer discretionary shares climbed by 2.9% on Thursday.
In trading on Thursday, real estate shares fell 0.4%.
Top Headline
Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) reported downbeat sales for its fiscal first quarter.
The Jack Ma co-founded e-commerce giant reported fiscal first-quarter 2024 revenue growth of 4% year-on-year to $33.47 billion, missing the analyst consensus estimate of $34.81 billion. Adjusted earnings per ADS of $2.26 beat the analyst consensus estimate of $2.13.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Cingulate Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CING#NASDAQ">CING</a>) shares shot up 147% to $4.5802 after the company was granted European patent No. 3261625 for CTx-1301, its lead asset for the treatment of ADHD.</li>
<li>Shares of AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) got a boost, surging 47% to $30.53 after the company said its first five commercial satellites are on target for orbital launch in the first half of September.</li>
<li>Gambling.com Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAMB#NASDAQ">GAMB</a>) shares were also up, gaining 26% to $11.12 following better-than-expected second-quarter financial results.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Turnstone Biologics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSBX#NASDAQ">TSBX</a>) shares dropped 59% to $0.8975 after the company reported worse-than-expected second-quarter EPS results.</li>
<li>Shares of SIGA Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) were down 26% to $8.82 after the National Institutes of Health&#8217;s National Institute of Allergy and Infectious Diseases announced topline results from a preliminary analysis of the PALM 007 trial of Tecovirimat for Monkeypox virus did not meet its primary endpoint.</li>
<li>Terran Orbital Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLAP#NYSE">LLAP</a>) was down, falling 41% to $0.2363. Lockheed Martin announced plans to acquire Terran Orbital.</li>
</ul>
Commodities In commodity news, oil traded up 1.4% to $78.09 while gold traded up 0.6% at $2,493.80.
Silver traded up 4.1% to $28.46 on Thursday, while copper rose 2.7% to $4.1490.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 1.15%, Germany's DAX rose 1.66% and France's CAC 40 rose 1.23%. Spain's IBEX 35 Index rose 1.23%, while London's FTSE 100 rose 0.80%.
The British economy grew by 0.9% year-over-year in the second quarter, recording the biggest annual growth rate since the third quarter of 2022. Labor productivity in the UK increased 0.3% on quarter during the second quarter. The UK&#8217;s trade deficit narrowed to £5.32 billion in June versus a revised £5.77 billion in the earlier month. Industrial production in the UK climbed 0.8% month-over-month for June.
Asia Pacific Markets
Asian markets closed mixed on Thursday, with Japan's Nikkei 225 jumping 0.78%, Hong Kong's Hang Seng Index falling 0.03% and China's Shanghai Composite Index gaining 0.94%.
Industrial production in Japan fell by 4.2% month-over-month during June, while Japanese economy expanded by 3.1% on an annualized basis in the second quarter. China&#8217;s retail sales climbed by 2.7% year-over-year in July versus market estimates of 2.6%. China's industrial production rose by 5.1% year-over-year in July.
Economics
<ul>
<li>U.S. retail sales gained 1% month-over-month in July versus a revised 0.2% decline in June and higher than market estimates of a 0.3% gain.</li>
<li>The Philadelphia Fed Manufacturing Index declined to -7 in August from 13.9 in July and versus market estimates of 7.</li>
<li>The NY Empire State Manufacturing Index rose to -4.7 in August, notching the highest level in six months.</li>
<li>Export prices increased 0.7% month-over-month in July, while import prices rose 0.1%.</li>
<li>U.S. initial jobless claims declined by 7,000 to 227,000 in the week ending August 10, versus market estimates of 235,000.</li>
<li>U.S industrial production declined by 0.6% from the prior month in July compared to a revised 0.3% gain in June.</li>
<li>The NAHB/Wells Fargo Housing Market Index declined to 39 in August, recording the lowest level so far in 2024.</li>
<li>Total business inventories increased by 0.3% month-over-month in June compared to a 0.5% rise in the earlier month.</li>
<li>U.S. natural-gas supplies fell 6 billion cubic feet during the week ended Aug. 9.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/analyst-ratings/downgrades/24/08/40393124/this-snowflake-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-thursday">This Snowflake Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday</a>

Equities

Eurozone

Commodities

CING

GAMB

LLAP

TSBX

Crude Oil Gains Over 1%; Alibaba Posts Weak Revenue

Several healthcare stocks associated with mpox are seeing increased attention Thursday after the World Health Organization&nbsp;declared a public health emergency in response to an <a href="https://www.benzinga.com/general/health-care/24/08/40381585/who-declares-mpox-public-health-emergency-coordinated-international-response-essential-to-hal">mpox outbreak in Africa</a>.
What Happened: WHO Director-General Tedros Adhanom Ghebreyesus determined this week that the recent surge of mpox, previously known as monkeypox, across a growing number of countries in Africa constitutes a public health emergency of international concern under International Health Regulations.
&#8220;The emergence of a new clade of mpox, its rapid spread in eastern DRC, and the reporting of cases in several neighbouring countries are very worrying. On top of outbreaks of other mpox clades in DRC and other countries in Africa, it's clear that a coordinated international response is needed to stop these outbreaks and save lives,&#8221; the WHO Director-General <a href="https://www.who.int/news/item/14-08-2024-who-director-general-declares-mpox-outbreak-a-public-health-emergency-of-international-concern">said</a>.
Several stocks surged on the news Wednesday including Emergent Biosolutions Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>), which owns one of two vaccines that have been recommended by the Centers for Disease Control and Prevention (CDC): ACAM2000. Bavarian Nordic&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BVNRY#OTC">BVNRY</a>) JYNNEOS is the other CDC recommended vaccine for mpox.
See Also: <a href="https://www.benzinga.com/general/health-care/24/08/40381585/who-declares-mpox-public-health-emergency-coordinated-international-response-essential-to-hal">WHO Declares Mpox Public Health Emergency: &#8216;Coordinated International Response Essential&#8217; To Halt Outbreak</a>
Shares of GeoVax Labs Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) and SIGA Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) also traded higher on Wednesday, but they are moving in different directions Thursday. 
Geovax Labs&nbsp;is a clinical-stage biotechnology company engaged in developing immunotherapies and vaccines against cancers and infectious diseases.&nbsp;The company previously published information&nbsp;in&nbsp;peer-reviewed journals suggesting its vaccines help prevent mpox. GeoVax shares were up approximately 83% over the past week at the time of writing.
SIGA Technologies&nbsp;is a commercial-stage pharmaceutical company focused on the health security market. The company&#8217;s lead product is TPOXX (tecovirimat), an orally administered antiviral drug for the treatment of human smallpox disease.&nbsp;Mpox is in the same virus family as smallpox, but&nbsp;it causes milder symptoms.
SIGA Technologies shares soared on Wednesday, but the stock is giving back all of its gains on Thursday after&nbsp;the National Institute of Allergy and Infectious Diseases announced top-line results from a preliminary analysis of a trial testing TPOXX for mpox virus did not meet its primary endpoint.
Although the study did not meet statistical significance, SIGA said results suggest TPOXX provides clinical benefit compared to placebo in patients who are treated early and in patents with severe disease.
&#8220;We believe these data warrant further investigation and support our view that post exposure prophylaxis will be vital for treatment of severe cases of mpox and all cases of smallpox,&#8221; said Dennis Hruby, chief scientific officer of SIGA Technologies.
SIGA noted that additional studies are being conducted by trial sponsors around the world. These clinical trials are expected to help the company gain a deeper understanding of the potential for TPOXX to benefit patients with mpox.&nbsp;
Related Link: <a href="https://www.benzinga.com/general/biotech/24/08/40394363/in-nih-cosponsored-monkeypox-virus-study-in-congo-siga-technologies-antiviral-tecovirimat-did-not">In NIH-Cosponsored Monkeypox Virus Study In Congo, SIGA Technologies&#8217; Antiviral Tecovirimat Did Not Improve Lesion Resolution, Stock Tanks</a>
EBS, BNVRY, GOVX, SIGA Price Action: At publication time, Emergent Biosolutions shares were up 12.3% at $8.50, Bavarian Nordic shares were down 9.77% at $12.28, Geovax shares were up 13.5% at $3.69 and SIGA shares were down 29.4% at $8.45, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Emergent Biosolutions, Bavarian Nordic, GeoVax And SIGA Technologies Shares Are Making Big Moves Thursday: What's Going On?

AEMD

CMRX

MRNA

TNXP

Vaccine Group Gavi Says It Has Up To $500M Available For Mpox Response

The Russell 2000 is set for its strongest session in a month, bolstered by renewed confidence in the U.S. economy&#8217;s resilience after recession fears rattled <a href="https://www.benzinga.com/markets">markets earlier this month.</a>
The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) was up 2.8% Thursday afternoon, battling for its best one-day session since July 16, when it rallied 3.4%. The small-cap index outperformed the larger-cap indices, highlighting its heightened sensitivity to economic data.
<h3 class="wp-block-heading">Economic Data Fuels Small-Cap Rebound</h3>
The optimism surrounding the Russell 2000 was bolstered by the release of robust economic data on Thursday. Retail sales for July 2024 exceeded expectations, while initial jobless claims for the previous week came in lower than anticipated, countering recession fears.
Retail sales jumped 1% month-over-month in July, marking a sharp rebound from the downwardly revised 0.2% decline in June. This increase far surpassed the expected 0.3% gain and marked the most significant rise since January 2023. The surge was led by a 3.6% increase in sales at motor vehicle and parts dealers, followed by a 1.6% rise in sales at electronics and appliance stores.
On the labor market front, initial jobless claims fell from 234,000 to 227,000 for the week ending Aug. 10, defying market expectations of an increase to 235,000. This marks the second consecutive weekly decline since jobless claims reached a near-one-year high of 250,000 in late July.
Don&#8217;t miss out on this unparalleled opportunity:
<ul>
<li><a href="https://www.benzinga.com/events/small-cap/global-small-cap-conference-2024/" target="_blank" rel="noreferrer noopener">Register now to secure your spot at Benzinga&#8217;s Largest SmallCap Conference ever in Chicago!</a></li>
</ul>
<h3 class="wp-block-heading">Economist Takes</h3>
&#8220;The July retail sales data were consistent with our soft-landing economic outlook,&#8221; said Aditya Bhave, Bank of America economist. 
Bhave highlighted that the retail sales control group, which represents over a quarter of total personal consumption expenditures (PCE) and more than 80% of goods spending, has seen annualized increases of 6.8% and 4.4% over the past three and six months, respectively.
&#8220;With inflation cooling off, retail spending is still clearly running above trend. The decline in jobless claims reported today supports our view that a still-solid labor market is propping up consumer spending,&#8221; Bhave added.
In response to Thursday&#8217;s economic data, traders adjusted their expectations for future Federal Reserve rate cuts. The probability of a 25-basis-point rate cut has now increased to 77%, up from 64% just a day earlier and 45% a week ago.
David Morrison, senior market analyst at Trade Nation, stated, &#8220;It appears that the issues caused by the unwinding of the yen carry-trade, the frothiness of the tech sector, and U.S. recession fears have now dissipated. Investors are in a much better mood than they were 10 days ago, although a period of consolidation may be required to fully digest recent gains.&#8221;
<h3 class="wp-block-heading">Thursday&#8217;s Movers In The Russell 2000</h3>
The top five performers within the Russell 2000 index on Thursday were: 
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>% (1-day)</td>
</tr>
<tr>
<td>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>)</td>
<td>40.89</td>
</tr>
<tr>
<td>Accuray Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>)</td>
<td>33.43</td>
</tr>
<tr>
<td>Gambling.com Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAMB#NASDAQ">GAMB</a>)</td>
<td>26.22</td>
</tr>
<tr>
<td>Perpetua Resources Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPTA#NASDAQ">PPTA</a>)</td>
<td>24.24</td>
</tr>
<tr>
<td>Telos Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLS#NASDAQ">TLS</a>) </td>
<td>24.15</td>
</tr>
</tbody>
</table>
</figure>
Conversely, the top five losers were:
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>% (1-day)</td>
</tr>
<tr>
<td>Terran Orbital Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLAP#NYSE">LLAP</a>)</td>
<td>-41.26%</td>
</tr>
<tr>
<td>SIGA Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>)</td>
<td>-34.15</td>
</tr>
<tr>
<td>Spire Global, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) </td>
<td>-30.05</td>
</tr>
<tr>
<td>B. Riley Financial, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RILY#NASDAQ">RILY</a>)</td>
<td>-26.53</td>
</tr>
<tr>
<td>Titan Machinery Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TITN#NASDAQ">TITN</a>)</td>
<td>-10.16</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">Join Us At The Benzinga Small Cap Conference</h3>
Stay ahead of the market trends in U.S. small-cap stocks and get in-depth insights from industry experts. Join us at the Benzinga Small Cap Conference in October. 
Secure your spot today by registering at <a href="https://www.benzinga.com/events/small-cap/global-small-cap-conference-2024">Benzinga Small Cap Conference</a>. Don&#8217;t miss this opportunity to gain valuable knowledge and network with key players in the small-cap space.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/08/40399595/bill-ackman-cuts-chipotle-stake-right-before-stock-drop-did-billionaire-see-what-the-market-coul">Bill Ackman Cuts Chipotle Stake Right Before Stock Drop: Did Billionaire See What The Market Couldn&#8217;t?</a></li>
</ul>
Photo: Shutterstock

Macro Economic Events

Broad U.S. Equity ETFs

Retail Sales

Small Cap

Econ #s

Economics

ARAY

PPTA

RILY

SPIR

TITN

Russell 2000 Set For Strongest Session In A Month As US Economy Defies Recession Fears: Small Cap Movers On Thursday

WHO Says Actively Engaging With Swedish Health Authorities On Managing First Confirmed Case Of Mpox Clade Ib, Our Advice To Member States Going Forward

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 2% on Thursday.
The Dow traded up 1.25% to 40,509.36 while the NASDAQ jumped 2.24% to 17,577.21. The S&amp;P 500 also rose, gaining, 1.51% to 5,537.70.
Check This Out: <a href="https://www.benzinga.com/news/24/08/40391883/wall-streets-most-accurate-analysts-spotlight-on-3-materials-stocks-with-over-4-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Materials Stocks With Over 4% Dividend Yields</a>
Leading and Lagging Sectors Consumer discretionary shares climbed by 2.8% on Thursday.
In trading on Thursday, utilities shares fell 0.3%.
Top Headline
Walmart Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) announced strong second-quarter results and raised full-year guidance.
The retailer reported adjusted EPS of 67 cents (+9.8% Y/Y), beating the consensus of 64 cents. Sales were $169.34 billion, up 4.8% year over year or 5.0% (at constant currency), beating the consensus of $168.57 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Cingulate Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CING#NASDAQ">CING</a>) shares shot up 123% to $4.1299 after the company was granted European patent No. 3261625 for CTx-1301, its lead asset for the treatment of ADHD.</li>
<li>Shares of AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) got a boost, surging 28% to $26.58 after the company said its first five commercial satellites are on target for orbital launch in the first half of September.</li>
<li>SciSparc Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRC#NASDAQ">SPRC</a>) shares were also up, gaining 43% to $0.4599 after the company announced the courts approval to convene a meeting of shareholders to approve a merger with AutoMax.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Turnstone Biologics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSBX#NASDAQ">TSBX</a>) shares dropped 52% to $1.0598 after the company reported worse-than-expected second-quarter EPS results.</li>
<li>Shares of SIGA Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) were down 33% to $8.06 after the National Institutes of Health&#8217;s National Institute of Allergy and Infectious Diseases announced topline results from a preliminary analysis of the PALM 007 trial of Tecovirimat for Monkeypox virus did not meet its primary endpoint.</li>
<li>Terran Orbital Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLAP#NYSE">LLAP</a>) was down, falling 40% to $0.2381. Lockheed Martin announced plans to acquire Terran Orbital.</li>
</ul>
Commodities In commodity news, oil traded up 1.5% to $78.19 while gold traded up 0.5% at $2,492.00.
Silver traded up 3.9% to $28.395 on Thursday, while copper rose 3% to $4.16.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 1.18%, Germany's DAX rose 1.67% and France's CAC 40 rose 1.25%. Spain's IBEX 35 Index rose 1.16%, while London's FTSE 100 rose 0.74%.
The British economy grew by 0.9% year-over-year in the second quarter, recording the biggest annual growth rate since the third quarter of 2022. Labor productivity in the UK increased 0.3% on quarter during the second quarter. The UK&#8217;s trade deficit narrowed to £5.32 billion in June versus a revised £5.77 billion in the earlier month. Industrial production in the UK climbed 0.8% month-over-month for June.
Asia Pacific Markets
Asian markets closed mixed on Thursday, with Japan's Nikkei 225 jumping 0.78%, Hong Kong's Hang Seng Index falling 0.03% and China's Shanghai Composite Index gaining 0.94%.
Industrial production in Japan fell by 4.2% month-over-month during June, while Japanese economy expanded by 3.1% on an annualized basis in the second quarter. China&#8217;s retail sales climbed by 2.7% year-over-year in July versus market estimates of 2.6%. China's industrial production rose by 5.1% year-over-year in July.
Economics
<ul>
<li>U.S. retail sales gained 1% month-over-month in July versus a revised 0.2% decline in June and higher than market estimates of a 0.3% gain.</li>
<li>The Philadelphia Fed Manufacturing Index declined to -7 in August from 13.9 in July and versus market estimates of 7.</li>
<li>The NY Empire State Manufacturing Index rose to -4.7 in August, notching the highest level in six months.</li>
<li>Export prices increased 0.7% month-over-month in July, while import prices rose 0.1%.</li>
<li>U.S. initial jobless claims declined by 7,000 to 227,000 in the week ending August 10, versus market estimates of 235,000.</li>
<li>U.S industrial production declined by 0.6% from the prior month in July compared to a revised 0.3% gain in June.</li>
<li>The NAHB/Wells Fargo Housing Market Index declined to 39 in August, recording the lowest level so far in 2024.</li>
<li>Total business inventories increased by 0.3% month-over-month in June compared to a 0.5% rise in the earlier month.</li>
<li>U.S. natural-gas supplies fell 6 billion cubic feet during the week ended Aug. 9.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/analyst-ratings/downgrades/24/08/40393124/this-snowflake-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-thursday">This Snowflake Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday</a>

Earnings

SPRC

Nasdaq Jumps Over 2%; Walmart Earnings Top Views

<a href="https://x.com/AFP/status/1824110705642963055" title="https://x.com/AFP/status/1824110705642963055">https://x.com/AFP/status/1824110705642963055</a>

Macro Notification

Sweden Reports First Mpox Clade 1 Case Outside Africa, According To Public Health Agency - AFP

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 500 points on Thursday.
Following the market opening Thursday, the Dow traded up 1.29% to 40,523.31 while the NASDAQ jumped 1.34% to 17,423.38. The S&amp;P 500 also rose, gaining, 1.09% to 5,514.51.
Check This Out: <a href="https://www.benzinga.com/news/24/08/40391883/wall-streets-most-accurate-analysts-spotlight-on-3-materials-stocks-with-over-4-dividend-yields"> Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Materials Stocks With Over 4% Dividend Yields</a>
Leading and Lagging Sectors Consumer discretionary shares climbed by 2.6% on Thursday.
In trading on Thursday, utilities shares fell 0.6%.
Top Headline
U.S. retail sales gained 1% month-over-month in July versus a revised 0.2% decline in June and higher than market estimates of a 0.3% gain.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Cingulate Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CING#NASDAQ">CING</a>) shares shot up 149% to $4.60 after the company was granted European patent No. 3261625 for CTx-1301, its lead asset for the treatment of ADHD.</li>
<li>Shares of VS MEDIA Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSME#NASDAQ">VSME</a>) got a boost, surging 61% to $1.1500.</li>
<li>SciSparc Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRC#NASDAQ">SPRC</a>) shares were also up, gaining 45% to $0.4671 after the company announced the courts approval to convene a meeting of shareholders to approve a merger with AutoMax.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Turnstone Biologics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSBX#NASDAQ">TSBX</a>) shares dropped 49% to $1.1137 after the company reported worse-than-expected second-quarter EPS results.</li>
<li>Shares of SIGA Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) were down 40% to $7.19 after the National Institutes of Health&#8217;s National Institute of Allergy and Infectious Diseases announced topline results from a preliminary analysis of the PALM 007 trial of Tecovirimat for Monkeypox virus did not meet its primary endpoint.</li>
<li>Terran Orbital Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLAP#NYSE">LLAP</a>) was down, falling 37% to $0.2522. Lockheed Martin announced plans to acquire Terran Orbital.</li>
</ul>
Commodities In commodity news, oil traded up 1.2% to $77.89 while gold traded up 0.1% at $2,481.90.
Silver traded up 3.1% to $28.175 on Thursday, while copper rose 2.2% to $4.13.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 1.1%, Germany's DAX rose 1.3% and France's CAC 40 rose 1.1%. Spain's IBEX 35 Index rose 1%, while London's FTSE 100 rose 0.8%.
The British economy grew by 0.9% year-over-year in the second quarter, recording the biggest annual growth rate since the third quarter of 2022. Labor productivity in the UK increased 0.3% on quarter during the second quarter. The UK&#8217;s trade deficit narrowed to £5.32 billion in June versus a revised £5.77 billion in the earlier month. Industrial production in the UK climbed 0.8% month-over-month for June.
Asia Pacific Markets
Asian markets closed mixed on Thursday, with Japan's Nikkei 225 jumping 0.78%, Hong Kong's Hang Seng Index falling 0.03% and China's Shanghai Composite Index gaining 0.94%.
Industrial production in Japan fell by 4.2% month-over-month during June, while Japanese economy expanded by 3.1% on an annualized basis in the second quarter. China&#8217;s retail sales climbed by 2.7% year-over-year in July versus market estimates of 2.6%. China's industrial production rose by 5.1% year-over-year in July.
Economics
<ul>
<li>U.S. retail sales gained 1% month-over-month in July versus a revised 0.2% decline in June and higher than market estimates of a 0.3% gain.</li>
<li>The Philadelphia Fed Manufacturing Index declined to -7 in August from 13.9 in July and versus market estimates of 7.</li>
<li>The NY Empire State Manufacturing Index rose to -4.7 in August, notching the highest level in six months.</li>
<li>Export prices increased 0.7% month-over-month in July, while import prices rose 0.1%.</li>
<li>U.S. initial jobless claims declined by 7,000 to 227,000 in the week ending August 10, versus market estimates of 235,000.</li>
<li>U.S industrial production declined by 0.6% from the prior month in July compared to a revised 0.3% gain in June.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/downgrades/24/08/40393124/this-snowflake-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-thursday">This Snowflake Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday</a></li>
</ul>

VSME

Dow Surges Over 500 Points; US Retail Sales Rise In July

On Thursday, the National Institutes of Health&#8217;s National Institute of Allergy and Infectious Diseases (NIAID) announced topline results from a preliminary analysis of the PALM 007 trial of tecovirimat for the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/g40391369/topline-results-from-palm-007-study-of-sigas-tecovirimat-in-treatment-of-mpox-released" rel="noreferrer noopener">treatment of monkeypox virus (mpox)</a>.
SIGA Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) sells tecovirimat under Tpoxx, an antiviral medication against orthopoxviruses such as smallpox and mpox.
NIAID reported that the study did not meet its primary endpoint of a statistically significant improvement in time to lesion resolution within 28 days post-randomization for patients in the Democratic Republic of the Congo with mpox who were administered SIGA&#8217;s tecovirimat versus placebo.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/24/08/40381585/who-declares-mpox-public-health-emergency-coordinated-international-response-essential-to-hal" rel="noreferrer noopener">WHO Declares Mpox Public Health Emergency: &#8216;Coordinated International Response Essential&#8217; To Halt Outbreak</a>.
All patients in this study were hospitalized for the entire duration of treatment.
This study was not a registration study conducted under an FDA Investigational New Drug Application.
A meaningful improvement was observed in patients receiving tecovirimat whose symptoms began seven days or fewer before randomization and those with severe disease.
&#8220;We believe these data warrant further investigation and support our view that post-exposure prophylaxis will be vital for treatment of severe cases of mpox and all cases of smallpox,&#8221; stated Dennis Hruby, Chief Scientific Officer.
Additionally, in this study, tecovirimat exhibited a safety profile comparable to that of the placebo.
These results are consistent with several prior studies in healthy volunteers and further support the strong safety profile observed with tecovirimat over the past 15 years.
The PALM 007 study was part of a globally coordinated initiative to address the 2022 mpox outbreak in the DRC and worldwide.
In PALM 007, patients in the placebo arm had much more favorable outcomes than those in the observational studies from the DRC that were used to plan this trial, which could have reduced the measured benefit of tecovirimat compared to placebo.
The exact impact of this controlled environment on the trial results is not yet known.
However, the study&#8217;s 1.7% overall mortality among enrollees, regardless of whether they received the drug or not, was much <a target="_blank" href="https://www.nih.gov/news-events/news-releases/antiviral-tecovirimat-safe-did-not-improve-clade-i-mpox-resolution-democratic-republic-congo" rel="noreferrer noopener">lower</a> than the mpox mortality of 3.6% or higher reported among all cases in the DRC.
This shows that patients with mpox can achieve better outcomes when hospitalized and receive high-quality supportive care.
Price Action: SIGA stock is down 38.3% at $7.39 during the premarket session at last check Thursday.

In NIH-Cosponsored Mpox Virus Study In Congo, SIGA Technologies' Antiviral Tecovirimat Did Not Improve Lesion Resolution, Stock Tanks

SIGA Technologies shares are trading lower after the National Institutes of Health's National Institute of Allergy and Infectious Diseases announced topline results from a preliminary analysis of the PALM 007 trial of Tecovirimat for Mpox virus did not meet its primary endpoint.

SIGA Technologies CMO terminated

SIGA Technologies ( ($SIGA) ) just unveiled an announcement. SIGA Technologies, Inc. has revamped its compensation strategy for two key executives ...

SIGA Technologies Revamps Executive Compensation Strategy

SIGA Technologies to supply TPOXX in Morocco

The biotech industry offers a compelling investment opportunity due to its potential for disruptive innovations and high growth. Thus, investing in fundamentally strong small-cap stocks Esperion Therapeutics (ESPR), Innoviva, Inc. (INVA), and SIGA Technologies (SIGA) could be significantly rewarding. Read on… The biotech industry plays a crucial role in advancing healthcare through innovative therapies, genetic research, and drug development. The sector is driven by the demand for therapeutic treatments and genetic disorders cures, which is gaining momentum in the market.
Amid this, it could be wise to invest in fundamentally sound small-cap biotech stocks, Esperion Therapeutics, Inc. (<a href="https://stocknews.com/stock/ESPR/">ESPR</a>), Innoviva, Inc. (<a href="https://stocknews.com/stock/INVA/">INVA</a>), and SIGA Technologies, Inc. (<a href="https://stocknews.com/stock/SIGA/">SIGA</a>), with game-changing potential.
The biotech sector is witnessing heightened activity with firms working on breakthrough technologies. For instance, the broader biopharma sector had a strong second quarter, <a href="https://www.bioworld.com/articles/710642-despite-q2-drop-2024-h1-biopharma-financings-near-full-year-2023?v=preview">raising $22.94 billion</a>, and its half-year 2024 results were almost equal to the full-year 2023 results of $70 million.
Further, factors like increased funding and M&amp;A activities in Q2 are also the reason for such a favorable outlook for this sector. This year, there were <a href="https://investingnews.com/biotech-forecast/">28 merger and acquisition deals</a> where large pharma companies are investing in the research and development of small-cap companies.
According to <a href="https://www.precedenceresearch.com/biotechnology-market">Precedence research</a>, the global biotechnology market is anticipated to reach a value of $4.61 trillion by 2034, exhibiting a CAGR of 11.5%. This growth promises growth and explosive returns, driving market buzz and investment interest.
With that in mind, let's evaluate the fundamentals of the featured <a href="https://stocknews.com/category/biotech/">Biotech</a> industry stocks, starting with number three:
Stock #3: Esperion Therapeutics, Inc. (<a href="https://stocknews.com/stock/ESPR/">ESPR</a>)
ESPR, a pharmaceutical company, has a <a href="https://www.investopedia.com/terms/m/marketcapitalization.asp">market cap</a> of $415.99 million, and it develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL and NEXLIZET tablets for treating primary hyperlipidemia in adults who require additional LDL-C lowering.
On September 3, ESPR announced additional commercial and medicare coverage for NEXLETOL&#xAE; (bempedoic acid) and NEXLIZET&#xAE; (bempedoic acid and ezetimibe). This addition provides access to more than 65% of medicare lives and more than 92% of commercially insured lives, allowing the healthcare providers to easily prescribe it to primary and secondary prevention patients.
On May 22, ESPR and Daiichi Sankyo Europe GmbH jointly announced the approval from the European Commission (EC) for the label update of both NILEMDO and NUSTENDI. The treatment is to be used for hypercholesterolemia and to reduce the risk of adverse cardiovascular events.
For the six-month period that ended on June 30, 2024, ESPR's total revenues increased 322.2% year-over-year to $211.57 million, while the company reported net revenue of $53.06 million, indicating a 42.2% growth from the prior-year period.
Street expects ESPR's revenue for the fiscal third quarter (ended September 2024) to increase 55.7% year-over-year to $52.88 million. In addition, it surpassed the revenue estimates in each of the trailing four quarters, which is promising.
ESPR's stock has surged 153.6% over the past year to close the last trading session at $2.12.
ESPR's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect this robust outlook. The stock has an overall rating of B, which equates to Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
ESPR has a B grade for Growth, Value, and Quality. It is ranked #35 out of 330 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry. <a href="https://stocknews.com/stock/ESPR/">Click here</a> to see the additional ratings for ESPR (Momentum, Stability, and Sentiment).
Stock #2: Innoviva, Inc. (<a href="https://stocknews.com/stock/INVA/">INVA</a>)
With a market cap of $1.26 billion, INVA develops and commercializes pharmaceutical products internationally. It has a portfolio of royalties and other healthcare assets.  The company's products include RELVAR/BREO ELLIPTA, ANORO ELLIPTA, and TRELEGY ELLIPTA.
On May 20, INVA and Zai Lab Limited (<a href="https://stocknews.com/stock/ZLAB/">ZLAB</a>) received approval from China's National Medical Products Administration (NMPA) for XACDURO. It shall be used to treat hospital-acquired and ventilator-associated pneumonia caused by resistant Acinetobacter strains. This approval is a significant step toward combating antibiotic resistance.
In the six-month period that ended on June 30, 2024, INVA's total revenue increased 12.7% year-over-year to $177.40 million. The company's net income came in at $1.85 million or $0.03 per share for the period. INVA's cash and cash equivalents at the end of the period were $217 million, indicating 25.4% growth from the prior-year period.
Analysts expect INVA's revenue for the third quarter (ended September 2024) to increase 14.4% year-over-year to $76.91 million, while its EPS for the same period is expected to grow 47.2% from the prior year's period to $0.27. The company surpassed consensus revenue in three of the trailing four quarters, which is promising.
Over the past year, the stock has surged 50.7%, closing the last trading session at $20.21.
It's no surprise that INVA has an overall rating of B, equating to a Buy in our POWR Ratings system. It has an A grade for Value and a B for Quality. Out of 330 stocks in the same industry, INVA is ranked #31.
Beyond what is stated above, we've also rated INVA for Growth, Momentum, Stability, and Sentiment. Get all INVA ratings <a href="https://stocknews.com/stock/INVA/">here</a>.
Stock #1: SIGA Technologies, Inc. (<a href="https://stocknews.com/stock/SIGA/">SIGA</a>)
With a market capitalization of $485.31 million, SIGA is a commercial-stage pharmaceutical firm focused on the health security market. Its main offering is TPOXX, an oral antiviral drug intended to treat variola virus-induced smallpox in humans.
On October 8, SIGA announced an agreement to supply TPOXX (tecovirimat) in Morocco, collaborating with the Ministry of Health in Morocco. This agreement will help SIGA establish its global presence and mark its first commercial sale on the continent.
On August 21, SIGA announced that the U.S. Department of Defense (DOD) had procured approximately $9 million of TPOXX. This contract represents the third award from the DOD in the past three years.
SIGA, for the second quarter (ended June 30, 2024), reported total revenues of $21.81 million, indicating a 271% growth from the prior-year quarter, and its product sales and supportive services revenue increased significantly year-over-year to $20.68 million.
In addition, the company's net and comprehensive income stood at $1.83 million compared to the prior-year quarter's loss of $2.88 million, while its income per share came in at $0.03 versus a loss of $0.04 per share last year.
The consensus revenue estimate of $160.46 million for the fiscal year (ending December 2024) represents a 14.7% increase year-over-year. The consensus EPS estimate of $1 for the same quarter indicates a 5.1% improvement year-over-year.
The stock has gained 30.3% over the past nine months and 25% over the past year to close the last trading session at $6.80.
SIGA's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
It also has an A grade for Value and Quality and a B for Growth. Within the Biotech industry, it is ranked #16. <a href="https://stocknews.com/stock/SIGA/">Click here</a> to see SIGA's ratings for Momentum, Stability, and Sentiment.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>

<hr />
INVA shares were trading at $20.19 per share on Thursday afternoon, down $0.02 (-0.10%). Year-to-date, INVA has gained 25.87%, versus a 24.06% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Anushka Dutta</h2> <img src='https:/wp-content/uploads/2021/08/Anushka-Dutta_Headshot_3.jpg' style="float:left; padding:5px;width:125px;">Anushka is an analyst whose interest in understanding the impact of broader economic changes on financial markets motivated her to pursue a career in investment research.<a href="https://stocknews.com/authors/?author=anushka-dutta">More...</a>The post <a href=https://stocknews.com/news/inva-siga-espr-zlab-3-small-cap-biotech-stocks-with-game-changing-potential/>3 Small-Cap Biotech Stocks With Game-Changing Potential</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Small-Cap Biotech Stocks With Game-Changing Potential

SIGA Technologies (SIGA) entered into an agreement with Vanderbilt University to obtain a license to a portfolio of preclinical fully human monoclo...

Siga Technologies enters exclusive license agreement with Vanderbilt University

Germany's disease control agency, the Robert Koch Institute, announced that an mpox infection that was contracted abroad had been detected within t...

Germany finds mpox infection in country contracted abroad

First mpox case linked to African outbreak reported in U.K.

APDN

BVNKF

CODX

ESPR

INVA

RHHBY

ZLAB

Legal

Press Releases

SIGA Technologies (SIGA) Shares Tumble After Mpox Therapy Fails, Chief Medical Officer Terminated - Hagens Berman

SIGA ALERT: Bragar Eagel & Squire, P.C. is Investigating SIGA Technologies, Inc. on Behalf of SIGA Stockholders and Encourages Investors to Contact the Firm

SIGA Announces Agreement to Supply TPOXX® in Morocco

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating SIGA Technologies, Inc. for potential violations of federal securities laws

SIGA Enters into Exclusive License Agreement with Vanderbilt University for Novel Poxvirus Monoclonal Antibodies

Bragar Eagel & Squire, P.C. Is Investigating CSX, Stride, and SIGA and Encourages Investors to Contact the Firm

SIGA to Host Business Update Call on November 7 Following Release of Third-Quarter 2024 Financial Results

Comments

SIGA Technologies

Notizie

Ultime notizie per SIGA Technologies (NASDAQ:SIGA) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO